New triple-targeting pharmacological tool developed for cancer treatment

FHS
October 8, 2024
11:46 pm

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell.

Prabotulinumtoxin A biosimilar by AEON Biopharma for Spasmodic Torticollis (Cervical Dystonia): Likelihood of Approval

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia).

February 9, 2024

FDA Unveils Draft Guidance to Improve Pulse Oximeter Accuracy Across Skin Tones

Makers of medical devices that quickly measure oxygen levels in the blood would have to gather extra data to show that their products work for

January 8, 2025

Smart capsules: the future of gut health diagnosis and monitoring?

Researchers discussed using smart and robotic capsules for sampling and sensing the gut.

September 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.